Navigation Links
Scientists report successful vaccine developed against deadly Nipah virus
Date:8/8/2012

A team of federal and university scientists reports a major breakthrough in the development of a highly effective vaccine against the deadly Nipah virus. The results of their study, "A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge," will appear in Science Translational Medicine online. The full study will be available following the release of the embargo at 2 p.m. Aug. 8, 2012.

The research team members are a collaborative group of investigators from the Uniformed Services University of the Health Sciences (USU), the University of Texas Medical Branch (UTMB) and Galveston National Laboratory (GNL), the National Institutes of Health's (NIH's) National Institute of Allergy and Infectious Diseases (NIAID) and Rocky Mountain Laboratories (RML), and the Boston University School of Medicine and National Emerging Infectious Diseases Laboratories Institute (NEIDL). The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. provides technology transfer assistance in protecting the Nipah and Hendra virus vaccine developed at USU.

Nipah virus and Hendra virus emerged in the 1990s causing serious disease outbreaks in humans and livestock in Australia, Malaysia, Singapore, Bangladesh and India. Recent Nipah outbreaks have resulted in acute respiratory distress syndrome and encephalitis, person-to-person transmission, and greater than 75 percent case fatality rates among humans. The viruses are found naturally in several species of Pteropid fruit bats (flying foxes). The NIH and Centers for Disease Control and Prevention have classified Nipah and Hendra as biothreat agents, and the U.S. Department of Agriculture has characterized them as agriculture threat agents. In fact, the infectious agent of the recent cinematic release "Contagion" was modeled after Nipah virus.

In experiments carried out in African green monkeys at the RML in Hamilton, MT, where there is a high-level safety and security facility for working with live Nipah virus, the team of researchers, under the direction of Heinz Feldmann, M.D., Ph.D., chief of the RML, Laboratory of Virology, demonstrated that immunizing monkeys with a vaccine based on the Hendra virus attachment G glycoprotein afforded complete protection against Nipah virus infection with no evidence of disease.

"These findings are really quite promising and appear to offer a real potential treatment for either Nipah or Hendra virus infection in people," said Christopher C. Broder, Ph.D., professor of Microbiology at USU and study corresponding author.

The vaccine is a soluble portion of the G glycoprotein of Hendra virus, known as Hendra-sG, which mediates viral infection and is produced in the laboratory using molecular techniques. Lead author, Katharine Bossart, Ph.D., a USU alumna and assistant professor in the Department of Microbiology, Boston University School of Medicine, developed the Hendra-sG vaccine while a student in Dr. Broder's laboratory at USU. "Since the vaccine is only a recombinant piece of the virus, it can be produced by itself and purified, and is a type of vaccine known as a subunit, thus making it extremely safe to use," Dr. Bossart said.

According to study co-author Thomas W. Geisbert, Ph.D., professor in the Department of Microbiology and Immunology at UTMB and GNL, "This work now provides key evidence that a simple and safe recombinant vaccine against Nipah virus is possible. Demonstrating this in a nonhuman primate model is a major step forward in developing it for future therapeutic use in people."

Major support for the current study came from the NIAID, NIH, including grant U01-AI082121 awarded to Dr. Geisbert and R01-AI054715 to Dr. Broder.

"There are currently no approved vaccines for prevention of infection and disease caused by Nipah and Hendra for use people or livestock," Dr. Broder said. "The vaccine had previously shown protection in ferrets against Hendra virus infection, and in cats against Nipah virus infection. In addition, the Hendra-sG vaccine has been trialed in horses against Hendra virus in Australia where it has demonstrated complete protection against illness and infection. Demonstrating its potential as a safe and effective vaccine in monkeys is an important step toward being licensed for possible use in people."


'/>"/>

Contact: JoAnn Sperber
jsperber@hjf.org
240-694-2163
Henry M. Jackson Foundation for the Advancement of Military Medicine
Source:Eurekalert

Related biology technology :

1. Worlds smallest semiconductor laser created by University of Texas scientists
2. Scientists read monkeys inner thoughts
3. World record: Scientists from northern Germany produce the lightest material in the world
4. NineSigma Partners with Scientists Without Borders to Find New Sustainable Packaging for Micronutrient Powders that Combat Malnutrition
5. Scripps Research Institute scientists find easier way to make new drug compounds
6. Finding Brings Scientists One Step Closer To Parkinsons Drug
7. Stanford scientists spark new interest in the century-old Edison battery
8. Scientists gain understanding of self-cleaning gecko foot hair
9. WHEATON® Introduces a New Web Community for Scientists, Researchers, and Biopharmaceutical Packagers
10. Unzipped carbon nanotubes could help energize fuel cells and batteries, Stanford scientists say
11. UCLA scientists unlock mystery of how handedness arises
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... ... Shimadzu Scientific Instruments (SSI) will be showcasing a broad ... Expo. Shimadzu’s high-performance instruments enable laboratories to test cannabis products for potency, moisture, ... booth 1021 to learn how Shimadzu’s instruments can help improve QA/QC testing, peak ...
(Date:4/27/2016)... Columbia , April 27, 2016 ... "NanoStruck") (CSE: NSK) (OTCPink: NSKQB) ( Frankfurt ... Anschluss an ihre Pressemitteilung vom 13. August 2015 ... hat, ihre Finanzen um zusätzliche 200.000.000 Einheiten auf ... Kanadische Dollar zu bringen. Davon wurden 157.900.000 Einheiten ...
(Date:4/27/2016)... ... April 27, 2016 , ... NDA ... joined the company as an Expert Consultant. Mr. Clark was formerly a ... managing the development of small molecule monographs based on analytical methods. NDA ...
(Date:4/27/2016)... ... ... Global Stem Cells Group CEO Benito Novas announced that Duncan ... affiliate Kimera Labs in Miami. , In 2004, Ross received his Ph.D. in Immunology ... disorders and the suppression of graft vs. host disease (GVHD) under UM Professor Robert ...
Breaking Biology Technology:
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
(Date:3/22/2016)... , March 22, 2016 ... research report "Electronic Sensors Market for Consumer Industry by ... & Others), Application (Communication & IT, Entertainment, ... - Global Forecast to 2022", published by ... is expected to reach USD 26.76 Billion ...
(Date:3/17/2016)... 17, 2016 ABI Research, the leader ... global biometrics market will reach more than $30 ... from 2015. Consumer electronics, particularly smartphones, continue to ... anticipated to reach two billion shipments by 2021 ... Pavlakis , Research Analyst at ABI Research. "Surveillance ...
Breaking Biology News(10 mins):